Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator
- PMID: 24252154
- PMCID: PMC4034590
- DOI: 10.1111/anec.12119
Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator
Abstract
Background: The survival outcome following a sudden cardiac arrest (SCA) in hemodialysis (HD) patients is poor regardless of whether an event takes place in or out of a dialysis center. The characteristics of SCA and post-SCA survival with HD patients using a wearable cardioverter defibrillator (WCD) are unknown.
Methods: All HD patients who were prescribed a WCD between 2004 and 2011 and experienced at least one SCA event were included in this study. Demographics, clinical background, characteristics of SCA events were identified from the manufacturer's database. An SCA event was defined as all sustained ventricular tachycardia/fibrillation (VT/VF) or asystole occurring within 24 hours of the index arrhythmia episode. The social security death index was used to determine mortality after WCD use.
Results: A total of 75 HD patients (mean age = 62.9 ± 11.7 years, female = 37.3%) experienced 84 SCA events (119 arrhythmia episodes) while wearing the WCD. Sixty six (78.6%) SCA events were due to VT/VF and 18 (21.4%) were due to asystole. Most SCA episodes occurred between 09:00 and 10:00 (RR = 2.82, 95% CI [1.05, 7.62], P < 0.0001), followed by the 13:00-14:00 time interval (RR = 2.22, 95% CI [0.79, 6.21], P = 0.006). Acute 24-hour survival was 70.7% for all SCA events; 30-day and 1-year survival were 50.7% and 31.4%, respectively. Women had a better post-SCA survival than men (HR = 2.41, 95% CI [1.09, 5.36], P = 0.03).
Conclusions: The use of WCD in HD patients was associated with improved post-SCA survival when compared to historical data.
Keywords: ESRD; hemodialysis hazards; mortality; sudden cardiac arrest; wearable cardioverter defibrillator.
©2013 ZOLL Medical. Annals of Noninvasive Electrocardiology published by Wiley Periodicals, Inc.
Figures




Similar articles
-
Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.JACC Clin Electrophysiol. 2017 Mar;3(3):243-250. doi: 10.1016/j.jacep.2016.09.002. Epub 2016 Nov 23. JACC Clin Electrophysiol. 2017. PMID: 29759518
-
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007. doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31. J Am Coll Cardiol. 2013. PMID: 23916930
-
Outcome of Patients With In-Hospital Ventricular Tachycardia and Ventricular Fibrillation Arrest While Using a Wearable Cardioverter Defibrillator.Am J Cardiol. 2018 Jan 15;121(2):205-209. doi: 10.1016/j.amjcard.2017.10.007. Epub 2017 Nov 16. Am J Cardiol. 2018. PMID: 29153771
-
Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis.JACC Clin Electrophysiol. 2019 Feb;5(2):152-161. doi: 10.1016/j.jacep.2018.11.011. Epub 2019 Jan 30. JACC Clin Electrophysiol. 2019. PMID: 30784684 Free PMC article.
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
Cited by
-
Cardiovascular complications in chronic dialysis patients.Curr Opin Nephrol Hypertens. 2016 Nov;25(6):536-544. doi: 10.1097/MNH.0000000000000280. Curr Opin Nephrol Hypertens. 2016. PMID: 27636771 Free PMC article. Review.
-
Case report: Death caused by multi-organ metastatic calcifications as a result of intramuscular injections with paraffin oil.Bone Rep. 2024 Mar 5;20:101749. doi: 10.1016/j.bonr.2024.101749. eCollection 2024 Mar. Bone Rep. 2024. PMID: 38487753 Free PMC article.
-
Subcutaneous versus Transvenous Implantable Cardioverter Defibrillator in Patients with End-Stage Renal Disease Requiring Dialysis: Extended Long-Term Retrospective Multicenter Follow-Up.J Pers Med. 2024 Aug 17;14(8):870. doi: 10.3390/jpm14080870. J Pers Med. 2024. PMID: 39202061 Free PMC article.
-
Atorvastatin, etanercept and the nephrogenic cardiac sympathetic remodeling in chronic renal failure rats.J Geriatr Cardiol. 2024 Apr 28;21(4):443-457. doi: 10.26599/1671-5411.2024.04.007. J Geriatr Cardiol. 2024. PMID: 38800544 Free PMC article.
-
Management of acute intradialytic cardiovascular complications: Updated overview (Review).Exp Ther Med. 2021 Mar;21(3):282. doi: 10.3892/etm.2021.9713. Epub 2021 Jan 26. Exp Ther Med. 2021. PMID: 33603889 Free PMC article. Review.
References
-
- Atlas of Chronic Kidney Disease and End‐Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 2012 Annual Data Report.
-
- Herzog CA, Li S, Weinhandl ED, et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818–825. - PubMed
-
- Redaelli B. Hydroelectrolytic equilibrium change in dialysis. J nephrol 2001;14(Suppl 4):S7–S11. - PubMed
-
- Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268–2273. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical